Review



glast creer  (Jackson Laboratory)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Jackson Laboratory glast creer
    VCAM1 is expressed in a subset of GLAST+ astrocytes in glioma-bearing mice. (A) Experimental timeline for glioma cell implantation in <t>GLAST-CreER::Ai14</t> mice. Mice received daily intraperitoneal injections of tamoxifen (TAM) for one week, followed by a one-week resting period. On day 1, 5,000-6,000 eGFP + 73C or GL261-luc glioma cells were implanted beneath the hippocampus. Tumor-bearing mice were harvested on day 10 (eGFP + 73C) or day 20 (GL261-luc). (B) Immunofluorescence staining of VCAM1 in eGFP + 73C gliomas at day 10 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (B) 1 mm; (a), 500 μm; (a’, b’), 100μm. (C) Immunofluorescence staining of VCAM1 in GL261-luc gliomas at day 20 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (C) 1 mm; (a), 500 μm; (a’), 100 μm.
    Glast Creer, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/glast creer/product/Jackson Laboratory
    Average 86 stars, based on 1 article reviews
    glast creer - by Bioz Stars, 2026-05
    86/100 stars

    Images

    1) Product Images from "Glia-derived VCAM1 promotes glioma progression"

    Article Title: Glia-derived VCAM1 promotes glioma progression

    Journal: Frontiers in Oncology

    doi: 10.3389/fonc.2026.1802953

    VCAM1 is expressed in a subset of GLAST+ astrocytes in glioma-bearing mice. (A) Experimental timeline for glioma cell implantation in GLAST-CreER::Ai14 mice. Mice received daily intraperitoneal injections of tamoxifen (TAM) for one week, followed by a one-week resting period. On day 1, 5,000-6,000 eGFP + 73C or GL261-luc glioma cells were implanted beneath the hippocampus. Tumor-bearing mice were harvested on day 10 (eGFP + 73C) or day 20 (GL261-luc). (B) Immunofluorescence staining of VCAM1 in eGFP + 73C gliomas at day 10 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (B) 1 mm; (a), 500 μm; (a’, b’), 100μm. (C) Immunofluorescence staining of VCAM1 in GL261-luc gliomas at day 20 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (C) 1 mm; (a), 500 μm; (a’), 100 μm.
    Figure Legend Snippet: VCAM1 is expressed in a subset of GLAST+ astrocytes in glioma-bearing mice. (A) Experimental timeline for glioma cell implantation in GLAST-CreER::Ai14 mice. Mice received daily intraperitoneal injections of tamoxifen (TAM) for one week, followed by a one-week resting period. On day 1, 5,000-6,000 eGFP + 73C or GL261-luc glioma cells were implanted beneath the hippocampus. Tumor-bearing mice were harvested on day 10 (eGFP + 73C) or day 20 (GL261-luc). (B) Immunofluorescence staining of VCAM1 in eGFP + 73C gliomas at day 10 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (B) 1 mm; (a), 500 μm; (a’, b’), 100μm. (C) Immunofluorescence staining of VCAM1 in GL261-luc gliomas at day 20 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (C) 1 mm; (a), 500 μm; (a’), 100 μm.

    Techniques Used: Immunofluorescence, Staining

    Knockout of VCAM1 in GLAST+ cells prolongs mouse survival. (A) Experimental timeline for glioma cell implantation in GLAST-CreER::VCAM1 fl/fl and control mice. Mice received daily intraperitoneal injections of tamoxifen (TAM) for one week, followed by a one-week waiting period. On day 1, 5,000-6,000 tumor cells were injected into the cortex or below the hippocampus. Live imaging analysis was conducted at the predetermined points. (B) Kaplan-Meier survival curves of mice implanted with eGFP+ 73C tumor cells below the hippocampus. Control group (n = 6), GLAST-CreER::VCAM1fl/fl group (n = 6). p-value calculated using the log-rank Mantel-Cox test. Control vs GLAST-CreER::VCAM1fl/fl, “ns” indicates no statistical significance ( p > 0.05). Here, p = 0.1209. (C) Kaplan-Meier survival curves of mice implanted with eGFP+ 73C tumor cells in the cortex. Control group (n = 6), GLAST-CreER::VCAM1fl/fl group (n = 6). p-value calculated using the log-rank Mantel-Cox test. Control vs GLAST-CreER::VCAM1fl/fl, ** p = 0.0053. (D) Live imaging analysis of GL261-luc-bearing mice in hippocampus GLAST-CreER::VCAM1 fl/fl and control groups at days 9, 28 and 50. (E) Kaplan-Meier survival curves of mice implanted with GL261-luc tumor cells below the hippocampus. Control group (n = 7), GLAST-CreER::VCAM1 fl/fl group (n = 6). p -value calculated using the log-rank Mantel-Cox test. Control vs. GLAST-CreER::VCAM1 fl/fl , * p = 0.0223. (F) Longitudinal quantification of tumor burden by bioluminescence imaging (Total Flux) in the Hippocampus GL261-luc models. Data are presented as mean ± SEM. Statistical significance was evaluated using Two-way repeated measures ANOVA. The asterisks indicate a significant interaction effect between time and genotype, ** p = 0.0082. Data are presented as mean ± SEM (n = 6–7 mice per group). Statistical significance was evaluated using two-way repeated measures ANOVA. (G) Live imaging analysis of GL261-luc-bearing mice in cortex from the GLAST-CreER::VCAM1 fl/fl and control groups at days 20, 40, 60. (H) Kaplan-Meier survival curves of mice implanted with GL261-luc tumor cells in the cortex. Control group (n = 7), GLAST-CreER::VCAM1 fl/fl group (n = 6). p -value calculated using the log-rank Mantel-Cox test. Control vs. GLAST-CreER::VCAM1 fl/fl , * p = 0.0465. (I) Longitudinal quantification of tumor burden by bioluminescence imaging (Total Flux) in the Cortex GL261-luc models. Data are presented as mean ± SEM. Statistical significance was evaluated using Two-way repeated measures ANOVA. The asterisks indicate a significant interaction effect between time and genotype, * p = 0.0106. Data are presented as mean ± SEM (n = 6–7 mice per group). Statistical significance was evaluated using two-way repeated measures ANOVA.
    Figure Legend Snippet: Knockout of VCAM1 in GLAST+ cells prolongs mouse survival. (A) Experimental timeline for glioma cell implantation in GLAST-CreER::VCAM1 fl/fl and control mice. Mice received daily intraperitoneal injections of tamoxifen (TAM) for one week, followed by a one-week waiting period. On day 1, 5,000-6,000 tumor cells were injected into the cortex or below the hippocampus. Live imaging analysis was conducted at the predetermined points. (B) Kaplan-Meier survival curves of mice implanted with eGFP+ 73C tumor cells below the hippocampus. Control group (n = 6), GLAST-CreER::VCAM1fl/fl group (n = 6). p-value calculated using the log-rank Mantel-Cox test. Control vs GLAST-CreER::VCAM1fl/fl, “ns” indicates no statistical significance ( p > 0.05). Here, p = 0.1209. (C) Kaplan-Meier survival curves of mice implanted with eGFP+ 73C tumor cells in the cortex. Control group (n = 6), GLAST-CreER::VCAM1fl/fl group (n = 6). p-value calculated using the log-rank Mantel-Cox test. Control vs GLAST-CreER::VCAM1fl/fl, ** p = 0.0053. (D) Live imaging analysis of GL261-luc-bearing mice in hippocampus GLAST-CreER::VCAM1 fl/fl and control groups at days 9, 28 and 50. (E) Kaplan-Meier survival curves of mice implanted with GL261-luc tumor cells below the hippocampus. Control group (n = 7), GLAST-CreER::VCAM1 fl/fl group (n = 6). p -value calculated using the log-rank Mantel-Cox test. Control vs. GLAST-CreER::VCAM1 fl/fl , * p = 0.0223. (F) Longitudinal quantification of tumor burden by bioluminescence imaging (Total Flux) in the Hippocampus GL261-luc models. Data are presented as mean ± SEM. Statistical significance was evaluated using Two-way repeated measures ANOVA. The asterisks indicate a significant interaction effect between time and genotype, ** p = 0.0082. Data are presented as mean ± SEM (n = 6–7 mice per group). Statistical significance was evaluated using two-way repeated measures ANOVA. (G) Live imaging analysis of GL261-luc-bearing mice in cortex from the GLAST-CreER::VCAM1 fl/fl and control groups at days 20, 40, 60. (H) Kaplan-Meier survival curves of mice implanted with GL261-luc tumor cells in the cortex. Control group (n = 7), GLAST-CreER::VCAM1 fl/fl group (n = 6). p -value calculated using the log-rank Mantel-Cox test. Control vs. GLAST-CreER::VCAM1 fl/fl , * p = 0.0465. (I) Longitudinal quantification of tumor burden by bioluminescence imaging (Total Flux) in the Cortex GL261-luc models. Data are presented as mean ± SEM. Statistical significance was evaluated using Two-way repeated measures ANOVA. The asterisks indicate a significant interaction effect between time and genotype, * p = 0.0106. Data are presented as mean ± SEM (n = 6–7 mice per group). Statistical significance was evaluated using two-way repeated measures ANOVA.

    Techniques Used: Knock-Out, Control, Injection, Imaging



    Similar Products

    glast creer  (Jackson Laboratory)
    86
    Jackson Laboratory glast creer
    VCAM1 is expressed in a subset of GLAST+ astrocytes in glioma-bearing mice. (A) Experimental timeline for glioma cell implantation in <t>GLAST-CreER::Ai14</t> mice. Mice received daily intraperitoneal injections of tamoxifen (TAM) for one week, followed by a one-week resting period. On day 1, 5,000-6,000 eGFP + 73C or GL261-luc glioma cells were implanted beneath the hippocampus. Tumor-bearing mice were harvested on day 10 (eGFP + 73C) or day 20 (GL261-luc). (B) Immunofluorescence staining of VCAM1 in eGFP + 73C gliomas at day 10 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (B) 1 mm; (a), 500 μm; (a’, b’), 100μm. (C) Immunofluorescence staining of VCAM1 in GL261-luc gliomas at day 20 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (C) 1 mm; (a), 500 μm; (a’), 100 μm.
    Glast Creer, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/glast creer/product/Jackson Laboratory
    Average 86 stars, based on 1 article reviews
    glast creer - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier
    glast creer mice  (Jackson Laboratory)
    86
    Jackson Laboratory glast creer mice
    VCAM1 is expressed in a subset of GLAST+ astrocytes in glioma-bearing mice. (A) Experimental timeline for glioma cell implantation in <t>GLAST-CreER::Ai14</t> mice. Mice received daily intraperitoneal injections of tamoxifen (TAM) for one week, followed by a one-week resting period. On day 1, 5,000-6,000 eGFP + 73C or GL261-luc glioma cells were implanted beneath the hippocampus. Tumor-bearing mice were harvested on day 10 (eGFP + 73C) or day 20 (GL261-luc). (B) Immunofluorescence staining of VCAM1 in eGFP + 73C gliomas at day 10 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (B) 1 mm; (a), 500 μm; (a’, b’), 100μm. (C) Immunofluorescence staining of VCAM1 in GL261-luc gliomas at day 20 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (C) 1 mm; (a), 500 μm; (a’), 100 μm.
    Glast Creer Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/glast creer mice/product/Jackson Laboratory
    Average 86 stars, based on 1 article reviews
    glast creer mice - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier
    glast-creer strain tg[slc1a3cre/ert]1nat, id 012586  (Johns Hopkins HealthCare)
    90
    Johns Hopkins HealthCare glast-creer strain tg[slc1a3cre/ert]1nat, id 012586
    VCAM1 is expressed in a subset of GLAST+ astrocytes in glioma-bearing mice. (A) Experimental timeline for glioma cell implantation in <t>GLAST-CreER::Ai14</t> mice. Mice received daily intraperitoneal injections of tamoxifen (TAM) for one week, followed by a one-week resting period. On day 1, 5,000-6,000 eGFP + 73C or GL261-luc glioma cells were implanted beneath the hippocampus. Tumor-bearing mice were harvested on day 10 (eGFP + 73C) or day 20 (GL261-luc). (B) Immunofluorescence staining of VCAM1 in eGFP + 73C gliomas at day 10 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (B) 1 mm; (a), 500 μm; (a’, b’), 100μm. (C) Immunofluorescence staining of VCAM1 in GL261-luc gliomas at day 20 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (C) 1 mm; (a), 500 μm; (a’), 100 μm.
    Glast Creer Strain Tg[Slc1a3cre/Ert]1nat, Id 012586, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/glast-creer strain tg[slc1a3cre/ert]1nat, id 012586/product/Johns Hopkins HealthCare
    Average 90 stars, based on 1 article reviews
    glast-creer strain tg[slc1a3cre/ert]1nat, id 012586 - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    glast-creer strain tg[slc1a3-cre/ert]1nat id 012586  (Johns Hopkins HealthCare)
    90
    Johns Hopkins HealthCare glast-creer strain tg[slc1a3-cre/ert]1nat id 012586
    VCAM1 is expressed in a subset of GLAST+ astrocytes in glioma-bearing mice. (A) Experimental timeline for glioma cell implantation in <t>GLAST-CreER::Ai14</t> mice. Mice received daily intraperitoneal injections of tamoxifen (TAM) for one week, followed by a one-week resting period. On day 1, 5,000-6,000 eGFP + 73C or GL261-luc glioma cells were implanted beneath the hippocampus. Tumor-bearing mice were harvested on day 10 (eGFP + 73C) or day 20 (GL261-luc). (B) Immunofluorescence staining of VCAM1 in eGFP + 73C gliomas at day 10 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (B) 1 mm; (a), 500 μm; (a’, b’), 100μm. (C) Immunofluorescence staining of VCAM1 in GL261-luc gliomas at day 20 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (C) 1 mm; (a), 500 μm; (a’), 100 μm.
    Glast Creer Strain Tg[Slc1a3 Cre/Ert]1nat Id 012586, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/glast-creer strain tg[slc1a3-cre/ert]1nat id 012586/product/Johns Hopkins HealthCare
    Average 90 stars, based on 1 article reviews
    glast-creer strain tg[slc1a3-cre/ert]1nat id 012586 - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    glast-creer, x r26-lsl-tdtomato (jax# 007914) x mobp-egfp  (Jackson Laboratory)
    90
    Jackson Laboratory glast-creer, x r26-lsl-tdtomato (jax# 007914) x mobp-egfp
    VCAM1 is expressed in a subset of GLAST+ astrocytes in glioma-bearing mice. (A) Experimental timeline for glioma cell implantation in <t>GLAST-CreER::Ai14</t> mice. Mice received daily intraperitoneal injections of tamoxifen (TAM) for one week, followed by a one-week resting period. On day 1, 5,000-6,000 eGFP + 73C or GL261-luc glioma cells were implanted beneath the hippocampus. Tumor-bearing mice were harvested on day 10 (eGFP + 73C) or day 20 (GL261-luc). (B) Immunofluorescence staining of VCAM1 in eGFP + 73C gliomas at day 10 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (B) 1 mm; (a), 500 μm; (a’, b’), 100μm. (C) Immunofluorescence staining of VCAM1 in GL261-luc gliomas at day 20 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (C) 1 mm; (a), 500 μm; (a’), 100 μm.
    Glast Creer, X R26 Lsl Tdtomato (Jax# 007914) X Mobp Egfp, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/glast-creer, x r26-lsl-tdtomato (jax# 007914) x mobp-egfp/product/Jackson Laboratory
    Average 90 stars, based on 1 article reviews
    glast-creer, x r26-lsl-tdtomato (jax# 007914) x mobp-egfp - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    glast-creer mouse line  (Jackson Laboratory)
    90
    Jackson Laboratory glast-creer mouse line
    VCAM1 is expressed in a subset of GLAST+ astrocytes in glioma-bearing mice. (A) Experimental timeline for glioma cell implantation in <t>GLAST-CreER::Ai14</t> mice. Mice received daily intraperitoneal injections of tamoxifen (TAM) for one week, followed by a one-week resting period. On day 1, 5,000-6,000 eGFP + 73C or GL261-luc glioma cells were implanted beneath the hippocampus. Tumor-bearing mice were harvested on day 10 (eGFP + 73C) or day 20 (GL261-luc). (B) Immunofluorescence staining of VCAM1 in eGFP + 73C gliomas at day 10 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (B) 1 mm; (a), 500 μm; (a’, b’), 100μm. (C) Immunofluorescence staining of VCAM1 in GL261-luc gliomas at day 20 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (C) 1 mm; (a), 500 μm; (a’), 100 μm.
    Glast Creer Mouse Line, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/glast-creer mouse line/product/Jackson Laboratory
    Average 90 stars, based on 1 article reviews
    glast-creer mouse line - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    glast-creer(tg(slc1a3-cre/ert)1nat/j mice  (Jackson Laboratory)
    90
    Jackson Laboratory glast-creer(tg(slc1a3-cre/ert)1nat/j mice
    VCAM1 is expressed in a subset of GLAST+ astrocytes in glioma-bearing mice. (A) Experimental timeline for glioma cell implantation in <t>GLAST-CreER::Ai14</t> mice. Mice received daily intraperitoneal injections of tamoxifen (TAM) for one week, followed by a one-week resting period. On day 1, 5,000-6,000 eGFP + 73C or GL261-luc glioma cells were implanted beneath the hippocampus. Tumor-bearing mice were harvested on day 10 (eGFP + 73C) or day 20 (GL261-luc). (B) Immunofluorescence staining of VCAM1 in eGFP + 73C gliomas at day 10 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (B) 1 mm; (a), 500 μm; (a’, b’), 100μm. (C) Immunofluorescence staining of VCAM1 in GL261-luc gliomas at day 20 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (C) 1 mm; (a), 500 μm; (a’), 100 μm.
    Glast Creer(tg(slc1a3 Cre/Ert)1nat/J Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/glast-creer(tg(slc1a3-cre/ert)1nat/j mice/product/Jackson Laboratory
    Average 90 stars, based on 1 article reviews
    glast-creer(tg(slc1a3-cre/ert)1nat/j mice - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    glast-creer transgenic mice  (Jackson Laboratory)
    90
    Jackson Laboratory glast-creer transgenic mice
    VCAM1 is expressed in a subset of GLAST+ astrocytes in glioma-bearing mice. (A) Experimental timeline for glioma cell implantation in <t>GLAST-CreER::Ai14</t> mice. Mice received daily intraperitoneal injections of tamoxifen (TAM) for one week, followed by a one-week resting period. On day 1, 5,000-6,000 eGFP + 73C or GL261-luc glioma cells were implanted beneath the hippocampus. Tumor-bearing mice were harvested on day 10 (eGFP + 73C) or day 20 (GL261-luc). (B) Immunofluorescence staining of VCAM1 in eGFP + 73C gliomas at day 10 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (B) 1 mm; (a), 500 μm; (a’, b’), 100μm. (C) Immunofluorescence staining of VCAM1 in GL261-luc gliomas at day 20 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (C) 1 mm; (a), 500 μm; (a’), 100 μm.
    Glast Creer Transgenic Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/glast-creer transgenic mice/product/Jackson Laboratory
    Average 90 stars, based on 1 article reviews
    glast-creer transgenic mice - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    VCAM1 is expressed in a subset of GLAST+ astrocytes in glioma-bearing mice. (A) Experimental timeline for glioma cell implantation in GLAST-CreER::Ai14 mice. Mice received daily intraperitoneal injections of tamoxifen (TAM) for one week, followed by a one-week resting period. On day 1, 5,000-6,000 eGFP + 73C or GL261-luc glioma cells were implanted beneath the hippocampus. Tumor-bearing mice were harvested on day 10 (eGFP + 73C) or day 20 (GL261-luc). (B) Immunofluorescence staining of VCAM1 in eGFP + 73C gliomas at day 10 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (B) 1 mm; (a), 500 μm; (a’, b’), 100μm. (C) Immunofluorescence staining of VCAM1 in GL261-luc gliomas at day 20 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (C) 1 mm; (a), 500 μm; (a’), 100 μm.

    Journal: Frontiers in Oncology

    Article Title: Glia-derived VCAM1 promotes glioma progression

    doi: 10.3389/fonc.2026.1802953

    Figure Lengend Snippet: VCAM1 is expressed in a subset of GLAST+ astrocytes in glioma-bearing mice. (A) Experimental timeline for glioma cell implantation in GLAST-CreER::Ai14 mice. Mice received daily intraperitoneal injections of tamoxifen (TAM) for one week, followed by a one-week resting period. On day 1, 5,000-6,000 eGFP + 73C or GL261-luc glioma cells were implanted beneath the hippocampus. Tumor-bearing mice were harvested on day 10 (eGFP + 73C) or day 20 (GL261-luc). (B) Immunofluorescence staining of VCAM1 in eGFP + 73C gliomas at day 10 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (B) 1 mm; (a), 500 μm; (a’, b’), 100μm. (C) Immunofluorescence staining of VCAM1 in GL261-luc gliomas at day 20 post-implantation of GLAST-CreER::Ai14 mice. Scale bars: (C) 1 mm; (a), 500 μm; (a’), 100 μm.

    Article Snippet: C57BL/6J (stock#000664), Ai14 line (stock #007914), GLAST-CreER line(stock#012586), VCAM1 fl/fl (stock#007665) were purchased from Jackson Laboratory.

    Techniques: Immunofluorescence, Staining

    Knockout of VCAM1 in GLAST+ cells prolongs mouse survival. (A) Experimental timeline for glioma cell implantation in GLAST-CreER::VCAM1 fl/fl and control mice. Mice received daily intraperitoneal injections of tamoxifen (TAM) for one week, followed by a one-week waiting period. On day 1, 5,000-6,000 tumor cells were injected into the cortex or below the hippocampus. Live imaging analysis was conducted at the predetermined points. (B) Kaplan-Meier survival curves of mice implanted with eGFP+ 73C tumor cells below the hippocampus. Control group (n = 6), GLAST-CreER::VCAM1fl/fl group (n = 6). p-value calculated using the log-rank Mantel-Cox test. Control vs GLAST-CreER::VCAM1fl/fl, “ns” indicates no statistical significance ( p > 0.05). Here, p = 0.1209. (C) Kaplan-Meier survival curves of mice implanted with eGFP+ 73C tumor cells in the cortex. Control group (n = 6), GLAST-CreER::VCAM1fl/fl group (n = 6). p-value calculated using the log-rank Mantel-Cox test. Control vs GLAST-CreER::VCAM1fl/fl, ** p = 0.0053. (D) Live imaging analysis of GL261-luc-bearing mice in hippocampus GLAST-CreER::VCAM1 fl/fl and control groups at days 9, 28 and 50. (E) Kaplan-Meier survival curves of mice implanted with GL261-luc tumor cells below the hippocampus. Control group (n = 7), GLAST-CreER::VCAM1 fl/fl group (n = 6). p -value calculated using the log-rank Mantel-Cox test. Control vs. GLAST-CreER::VCAM1 fl/fl , * p = 0.0223. (F) Longitudinal quantification of tumor burden by bioluminescence imaging (Total Flux) in the Hippocampus GL261-luc models. Data are presented as mean ± SEM. Statistical significance was evaluated using Two-way repeated measures ANOVA. The asterisks indicate a significant interaction effect between time and genotype, ** p = 0.0082. Data are presented as mean ± SEM (n = 6–7 mice per group). Statistical significance was evaluated using two-way repeated measures ANOVA. (G) Live imaging analysis of GL261-luc-bearing mice in cortex from the GLAST-CreER::VCAM1 fl/fl and control groups at days 20, 40, 60. (H) Kaplan-Meier survival curves of mice implanted with GL261-luc tumor cells in the cortex. Control group (n = 7), GLAST-CreER::VCAM1 fl/fl group (n = 6). p -value calculated using the log-rank Mantel-Cox test. Control vs. GLAST-CreER::VCAM1 fl/fl , * p = 0.0465. (I) Longitudinal quantification of tumor burden by bioluminescence imaging (Total Flux) in the Cortex GL261-luc models. Data are presented as mean ± SEM. Statistical significance was evaluated using Two-way repeated measures ANOVA. The asterisks indicate a significant interaction effect between time and genotype, * p = 0.0106. Data are presented as mean ± SEM (n = 6–7 mice per group). Statistical significance was evaluated using two-way repeated measures ANOVA.

    Journal: Frontiers in Oncology

    Article Title: Glia-derived VCAM1 promotes glioma progression

    doi: 10.3389/fonc.2026.1802953

    Figure Lengend Snippet: Knockout of VCAM1 in GLAST+ cells prolongs mouse survival. (A) Experimental timeline for glioma cell implantation in GLAST-CreER::VCAM1 fl/fl and control mice. Mice received daily intraperitoneal injections of tamoxifen (TAM) for one week, followed by a one-week waiting period. On day 1, 5,000-6,000 tumor cells were injected into the cortex or below the hippocampus. Live imaging analysis was conducted at the predetermined points. (B) Kaplan-Meier survival curves of mice implanted with eGFP+ 73C tumor cells below the hippocampus. Control group (n = 6), GLAST-CreER::VCAM1fl/fl group (n = 6). p-value calculated using the log-rank Mantel-Cox test. Control vs GLAST-CreER::VCAM1fl/fl, “ns” indicates no statistical significance ( p > 0.05). Here, p = 0.1209. (C) Kaplan-Meier survival curves of mice implanted with eGFP+ 73C tumor cells in the cortex. Control group (n = 6), GLAST-CreER::VCAM1fl/fl group (n = 6). p-value calculated using the log-rank Mantel-Cox test. Control vs GLAST-CreER::VCAM1fl/fl, ** p = 0.0053. (D) Live imaging analysis of GL261-luc-bearing mice in hippocampus GLAST-CreER::VCAM1 fl/fl and control groups at days 9, 28 and 50. (E) Kaplan-Meier survival curves of mice implanted with GL261-luc tumor cells below the hippocampus. Control group (n = 7), GLAST-CreER::VCAM1 fl/fl group (n = 6). p -value calculated using the log-rank Mantel-Cox test. Control vs. GLAST-CreER::VCAM1 fl/fl , * p = 0.0223. (F) Longitudinal quantification of tumor burden by bioluminescence imaging (Total Flux) in the Hippocampus GL261-luc models. Data are presented as mean ± SEM. Statistical significance was evaluated using Two-way repeated measures ANOVA. The asterisks indicate a significant interaction effect between time and genotype, ** p = 0.0082. Data are presented as mean ± SEM (n = 6–7 mice per group). Statistical significance was evaluated using two-way repeated measures ANOVA. (G) Live imaging analysis of GL261-luc-bearing mice in cortex from the GLAST-CreER::VCAM1 fl/fl and control groups at days 20, 40, 60. (H) Kaplan-Meier survival curves of mice implanted with GL261-luc tumor cells in the cortex. Control group (n = 7), GLAST-CreER::VCAM1 fl/fl group (n = 6). p -value calculated using the log-rank Mantel-Cox test. Control vs. GLAST-CreER::VCAM1 fl/fl , * p = 0.0465. (I) Longitudinal quantification of tumor burden by bioluminescence imaging (Total Flux) in the Cortex GL261-luc models. Data are presented as mean ± SEM. Statistical significance was evaluated using Two-way repeated measures ANOVA. The asterisks indicate a significant interaction effect between time and genotype, * p = 0.0106. Data are presented as mean ± SEM (n = 6–7 mice per group). Statistical significance was evaluated using two-way repeated measures ANOVA.

    Article Snippet: C57BL/6J (stock#000664), Ai14 line (stock #007914), GLAST-CreER line(stock#012586), VCAM1 fl/fl (stock#007665) were purchased from Jackson Laboratory.

    Techniques: Knock-Out, Control, Injection, Imaging